1404117-41-4

Basic information

• Product Name: C₂₆H₂₆ClN₅O₄S
• Synonyms: C₂₆H₂₆ClN₅O₄S
• CAS NO: 1404117-41-4
• Molecular Weight: 540.043
• Mol File: 1404117-41-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₆H₂₆ClN₅O₄S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₆H₂₆ClN₅O₄S(1404117-41-4)
• EPA Substance Registry System: C₂₆H₂₆ClN₅O₄S(1404117-41-4)

Safety Data

• Hazardous Substances Data: 1404117-41-4(Hazardous Substances Data)

Upstream product

• 1404117-72-1 C₂₂H₁₆Cl₂N₄O₄S 
• 1404117-70-9 C₂₂H₁₇ClN₄O₅S 
• 541-41-3 chloroformic acid ethyl ester 
• 59074-26-9 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 
• 3337-70-0 methyl ((4-nitrophenyl)sulfonyl)carbamate 

Relevant articles and documents

JD-5006 and JD-5037: Peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities

Analogs of SLV-319 (Ibipinibant), a CB1 receptor inverse agonist, were synthesized with functionality intended to limit brain exposure while maintaining the receptor affinity and selectivity of the parent compound. Structure activity relationships of this series, and pharmacology of two lead compounds, 16 (JD-5006) and 23 (JD-5037) showing little brain presence as indicated by tissue distribution and receptor occupancy studies, are described. Effects with one of these compounds on plasma triglyceride levels, liver weight and enzymes, glucose tolerance and insulin sensitivity support the approach that blockade of peripheral CB1 receptors is sufficient to produce many of the beneficial metabolic effects of globally active CB1 blockers. Thus, PR CB1 inverse agonists may indeed represent a safer alternative to highly brain-penetrant agents for the treatment of metabolic disorders, including diabetes, liver diseases, dyslipidemias, and obesity.